查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067479

美國醫療保健數據貨幣化市場（品質、治療結果和支付資訊）規模、佔有率和趨勢分析報告：按組織、產品類型、買方、買方和產品類型以及細分市場預測（2026-2033 年）

U.S. Healthcare Data Monetization Market For Quality, Outcomes & Payment Intelligence Size, Share & Trends Analysis Report By Entity, By Product Type, By Buyer, By Buyer Vs Product Type, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國醫療保健數據貨幣化市場概覽（品質、結果和支付資訊細分市場）

美國醫療保健數據貨幣化市場（服務提供市場），涵蓋品質、治療結果和支付信息，預計2025年規模為9.5544億美元，到2033年將達到17.0553億美元。預計2026年至2033年期間，該市場將以7.77%的複合年成長率成長。這一成長主要受以下因素驅動：醫療保健數據量（電子健康記錄（EHR）、保險理賠數據和穿戴式設備）的快速成長；對真實世界數據（RWD）和真實世界證據（RWE）的需求不斷成長；人工智慧、高級分析和雲端平台的日益普及；以及支付方對成本最佳化和風險管理的日益關注。

美國醫療保健生態系統正透過廣泛採用電子健康記錄(EHR)、影像系統、保險理賠資料庫和連網型設備，產生大量資料集。結構化和非結構化資料的指數級成長正在創造大規模的、可貨幣化的資產基礎，使醫療服務提供者和保險公司能夠將匿名資料集和洞察商業化。

此外，美國生命科學產業正經歷著一場重大變革，即利用真實世界數據（RWD）來補充傳統的臨床試驗數據，並產生真實世界證據（RWE）。製藥和生物技術公司正擴大利用這些資料集來最佳化臨床試驗設計、識別合格的患者群體、監測治療結果並支持監管申報。

此外，監管機構和保險公司越來越重視上市後證據，以評估藥物在真實世界中的有效性和成本效益。隨著對真實世界數據/真實世界證據的依賴性日益增強，對高品質、長期患者資料集的需求也日益旺盛，這反過來又促使醫療服務提供者和數據聚合商透過夥伴關係、許可協議和分析服務等方式實現數據資產的商業化。因此，數據商業化正深入滲透到藥物研發和商業化的整個生命週期。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 美國醫療保健數據貨幣化市場（品質、結果和支付資訊）：市場動態
  • 商業環境工具分析：美國醫療保健數據貨幣化市場—品質、結果和支付資訊：市場

第4章：美國醫療保健數據貨幣化市場：品質、治療結果和支付資訊：按營業單位潛在市場規模 (TAM)、可銷售潛在市場規模 (SAM)、市場規模 (SOM)、估算和趨勢分析

  • 美國醫療保健數據貨幣化市場：品質、治療結果和支付資訊——按目標機構分類：要點
  • 美國醫療保健數據貨幣化市場（涵蓋品質、治療結果和支付資訊）：2025 年和 2033 年市場趨勢和市場佔有率分析
  • 醫療相關機構
    • 產品類型
    • 買家類型
  • 醫療領域以外的其他營業單位

第5章：美國醫療保健數據貨幣化市場：品質、治療結果和支付資訊：基於買方和產品細分、SAM 和 SOM 的估算和趨勢分析

  • 美國醫療保健數據貨幣化市場（涵蓋品質、治療結果和付款資訊）：按買方和細分市場分類：要點
  • 美國醫療保健數據貨幣化市場（涵蓋品質、治療結果和支付資訊）：市場：波動分析和按買方細分市場分類的市場佔有率分析（2025 年和 2033 年）
  • 製藥公司
    • 臨床實驗室支援（檢測機構選擇、受試者篩選、可行性分析）
    • 醫療保健系統和醫療保健提供者
    • 安全性、用藥依從性、健康經濟學與結果研究（真實世界證據、用藥遵從性分析、藥物安全監測、結果追蹤）
    • 處方藥清單分析/商業性准入支援（市場准入、支付方策略、報銷分析）
  • 醫療保健系統和醫療保健提供者
    • 資料（電子健康記錄(EMR) + 計費資料 + 品質資料）
    • 洞見（護理缺口 + 工作分析）
    • 模型（VBC最佳化引擎）
  • 零售藥房
    • 數據（患者+處方箋+用藥依從性訊號）
    • 洞察（病患行為/處方箋續配最佳化）
    • 模型（藥物依從性/參與度引擎）
  • 其他不收取費用的醫療保健相關機構
    • 數據包
    • 洞察平台
    • API/嵌入式模型

第6章：美國醫療保健數據貨幣化市場：品質、治療結果和支付資訊：價格基準和 ACV 範圍（2025 年）

  • 按買家和產品類型分類的年度現金流基準
  • 按合約類型
  • 與定價和保險費決定因素相關的交叉性挑戰

第7章：美國醫療保健數據貨幣化市場：品質、治療結果和支付資訊：買方需求和支付意願 (WTP) 排名

  • 按買家和產品類型細分進行排名
  • 可觀察的需求訊號
  • 實施基準

第8章 競爭情勢

  • 公司分類
  • 公司簡介列表
    • Arcadia Solutions, LLC
    • Inovalon
    • IQVIA
    • Optum, Inc.
    • Komodo Health, Inc.
    • Cotiviti, Inc.
    • Symphony Health
    • Definitive Healthcare
    • Truveta
  • Monetization Models Overview
Product Code: GVR-4-68040-907-7

U.S. Healthcare Data Monetization Market For Quality, Outcomes & Payment Intelligence Summary

The U.S. healthcare data monetization market size for quality, outcomes & payment intelligence (serviceable obtainable market) was estimated at USD 955.44 million in 2025 and is projected to reach USD 1,705.53 million by 2033, growing at a CAGR of 7.77% from 2026 to 2033. This growth is driven by the rapid expansion of healthcare data volume (EHR, Claims, Wearables), rising demand for Real-World Data (RWD) & Real-World Evidence (RWE), increasing adoption of AI, advanced analytics & cloud platforms, and growing payer focus on cost optimization & risk management.

The U.S. healthcare ecosystem generates massive datasets through widespread adoption of electronic health records (EHRs), imaging systems, claims databases, and connected devices. This exponential growth in structured and unstructured data creates a large monetizable asset base, enabling providers and payers to commercialize de-identified datasets and insights.

Moreover, there is a significant shift in the U.S. life sciences ecosystem toward leveraging real-world data (RWD) and generating real-world evidence (RWE) to complement traditional clinical trial data. Pharmaceutical and biotechnology companies are increasingly utilizing these datasets to optimize clinical trial design, identify eligible patient populations, monitor treatment outcomes, and support regulatory submissions.

In addition, regulators and payers are placing greater emphasis on post-market evidence to assess drug efficacy and cost-effectiveness in real-world settings. This growing reliance on RWD/RWE has created a strong demand for high-quality, longitudinal patient datasets, encouraging healthcare providers and data aggregators to monetize their data assets through partnerships, licensing agreements, and analytics services. As a result, data monetization is becoming deeply embedded in the broader drug development and commercialization lifecycle.

U.S. Healthcare Data Monetization Market Report Segmentation

This report forecasts revenue growth analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. healthcare data monetization market for quality, outcomes & payment intelligence report based on entity, product type, buyer type, and buyer vs product sub-segmentation:

  • Entity Outlook (TAM, SAM & SOM, USD Million, 2021 - 2033)
  • Healthcare entities
  • Non-healthcare entities
  • Healthcare Entities Outlook (SAM & SOM, USD Million, 2021 - 2033)
  • By Product Type
    • Data Subscription (patient-level / aggregate / licensed datasets)
    • Insights-as-a-Service (curated analytics products)
    • Models / Decision Engines (AI-enabled predictive products)
  • By Buyer Type
    • Pharmaceutical Companies
    • Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
    • HCP & Customer Targeting (Physician targeting, segmentation, sales enablement)
    • Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
    • Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
    • Health Systems & Providers
    • Go-to-Market & Contracting (Value-based care enablement, service line optimization)
    • Quality & Care Gap Closure (HEDIS, Stars, performance improvement)
    • Network & Operational Optimization (Referral management, capacity optimization, leakage reduction)
    • Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
    • Retail Pharmacies
    • Independent Pharmacies
    • Chain Pharmacies
    • Other Non-Payer Healthcare Entities
  • Buyer vs Product Type Sub-Segmentation Outlook (SAM & SOM, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
    • Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
    • Data subscription (clinical + claims + quality datasets)
    • Insights service (trial feasibility analytics)
    • Model/engines (site selection AI tools)
    • HCP & Customer Targeting (Physician targeting, segmentation, sales enablement)
    • Data (HCP-level claims + quality signals)
    • Insights (targeting analytics)
    • Models (real-time targeting engines)
    • Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
    • Data (payer + quality + reimbursement datasets)
    • Insights (access analytics)
    • Models (pricing / access optimization tools)
    • Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
    • Data (payer + quality + reimbursement datasets)
    • Insights (access analytics)
    • Models (pricing / access optimization tools)
  • Health Systems & Providers
    • Data (EMR + claims + quality data)
    • Insights (care gap + operational analytics)
    • Models (VBC optimization engines)
  • Retail Pharmacies
    • Data (patient + prescription + adherence signals)
    • Insights (patient behavior / refill optimization)
    • Models (adherence / engagement engines)
  • Other Non-Payer Healthcare Entities
    • Data packages
    • Insights platforms
    • API / embedded models

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Methodology Architecture Overview
    • 1.5.1. Modeling framework
      • 1.5.1.1. Serviceable Obtainable Market (SOM) Analysis - Approach/Assumptions
        • 1.5.1.1.1. Commodity Flow Analysis
        • 1.5.1.1.2. Scenario-Based Penetration Modeling (2021 - 2033)
        • 1.5.1.1.3. Interpretation of the Penetration Model
      • 1.5.1.2. Total Addressable Market (TAM) Analysis - Approach/Assumptions
        • 1.5.1.2.1. Bottom-up estimation logic
        • 1.5.1.2.2. Top-down validation logic
        • 1.5.1.2.3. Triangulation framework
      • 1.5.1.3. QFD-Based Methodology for SOM Share Allocation
        • 1.5.1.3.1. Scenario-based SOM share allocation
  • 1.6. List of Secondary Sources
  • 1.7. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market attractiveness snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot
  • 2.4. Top 3 monetization pathways
  • 2.5. Priority use cases
  • 2.6. Key risks (regulatory + channel conflict)

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market - Market Dynamics
    • 3.1.1. Market Driver Analysis
    • 3.1.2. Market Restraint Analysis
    • 3.1.3. Market Opportunity Analysis
    • 3.1.4. Market Challenge Analysis
  • 3.2. Business Environmental Tools Analysis: U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market
    • 3.2.1. Porter's Five Forces Analysis
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTLE Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic and Social landscape
      • 3.2.2.3. Technological landscape
      • 3.2.2.4. Environmental landscape
      • 3.2.2.5. Legal Landscape

Chapter 4. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: By Entity TAM, SAM & SOM Estimates & Trend Analysis

  • 4.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity: Key Takeaways
  • 4.2. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market: Entity Movement & Market Share Analysis, 2025 & 2033
  • 4.3. Healthcare entities
    • 4.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2. Product Type
      • 4.3.2.1. Data Subscription (patient-level / aggregate / licensed datasets)
        • 4.3.2.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.2. Insights-as-a-Service (curated analytics products)
        • 4.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.3. Models / Decision Engines (AI-enabled predictive products)
        • 4.3.2.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3. Buyer Type
      • 4.3.3.1. Pharmaceutical Companies
        • 4.3.3.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.1.2. Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
          • 4.3.3.1.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.1.3. HCP & Customer Targeting (Physician targeting, segmentation, sales enablement)
          • 4.3.3.1.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.1.4. Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
          • 4.3.3.1.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.1.5. Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
          • 4.3.3.1.5.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2. Health Systems & Providers
        • 4.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.2.2. Go-to-Market & Contracting (Value-based care enablement, service line optimization)
          • 4.3.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.2.3. Quality & Care Gap Closure (HEDIS, Stars, performance improvement)
          • 4.3.3.2.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.2.4. Network & Operational Optimization (Referral management, capacity optimization, leakage reduction)
          • 4.3.3.2.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.2.5. Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
          • 4.3.3.2.5.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3. Retail Pharmacies
        • 4.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.3.2. Independent Pharmacies
          • 4.3.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
        • 4.3.3.3.3. Chain Pharmacies
          • 4.3.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.4. Other Non-Payer Healthcare Entities
        • 4.3.3.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Non-healthcare entities
    • 4.4.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer vs Product Type Sub-Segmentation SAM & SOM Estimates & Trend Analysis

  • 5.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer vs Sub-Segmentation: Key Takeaways
  • 5.2. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market: Buyer X Sub-Segmentation Movement & Market Share Analysis, 2025 & 2033
  • 5.3. Pharmaceutical Companies
    • 5.3.1. Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
      • 5.3.1.1. Data subscription (clinical + claims + quality datasets)
        • 5.3.1.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.1.2. Insights service (trial feasibility analytics)
        • 5.3.1.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.1.3. Model/engines (site selection AI tools)
        • 5.3.1.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.2. Health Systems & Providers
      • 5.3.2.1. Data (HCP-level claims + quality signals)
        • 5.3.2.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.2. Insights (targeting analytics)
        • 5.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.2.3. Models (real-time targeting engines)
        • 5.3.2.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.3. Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
      • 5.3.3.1. Data (payer + quality + reimbursement datasets)
        • 5.3.3.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.2. Insights (access analytics)
        • 5.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.3.3. Models (pricing / access optimization tools)
        • 5.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.4. Formulary Analytics/Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
      • 5.3.4.1. Data (payer + quality + reimbursement datasets)
        • 5.3.4.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.4.2. Insights (access analytics)
        • 5.3.4.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.3.4.3. Models (pricing / access optimization tools)
        • 5.3.4.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Health Systems & Providers
    • 5.4.1. Data (EMR + claims + quality data)
      • 5.4.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Insights (care gap + operational analytics)
      • 5.4.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Models (VBC optimization engines)
      • 5.4.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Data (patient + prescription + adherence signals)
      • 5.5.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Insights (patient behavior / refill optimization)
      • 5.5.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Models (adherence / engagement engines)
      • 5.5.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Other Non-Payer Healthcare Entities
    • 5.6.1. Data packages
      • 5.6.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.2. Insights platforms
      • 5.6.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.3. API/embedded models
      • 5.6.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Pricing Benchmarks and ACV Ranges (2025)

  • 6.1. Buyer X Product Type ACV Benchmarks
    • 6.1.1. Pharmaceutical Companies
      • 6.1.1.1. Clinical Trial Enablement
        • 6.1.1.1.1. Data subscription (clinical + claims + quality datasets)
        • 6.1.1.1.2. Insights service (trial feasibility analytics)
        • 6.1.1.1.3. Model/engines (site selection AI tools)
      • 6.1.1.2. Health Systems & Providers
        • 6.1.1.2.1. Data (HCP-level claims + quality signals)
        • 6.1.1.2.2. Insights (targeting analytics)
        • 6.1.1.2.3. Models (real-time targeting engines)
      • 6.1.1.3. Safety, Adherence & HEOR
        • 6.1.1.3.1. Data (payer + quality + reimbursement datasets)
        • 6.1.1.3.2. Insights (access analytics)
        • 6.1.1.3.3. Models (pricing / access optimization tools)
      • 6.1.1.4. Formulary Analytics/Commercial Access Enablement
        • 6.1.1.4.1. Data (payer + quality + reimbursement datasets)
        • 6.1.1.4.2. Insights (access analytics)
        • 6.1.1.4.3. Models (pricing / access optimization tools)
    • 6.1.2. Health Systems & Providers
      • 6.1.2.1. Data (EMR + claims + quality data)
      • 6.1.2.2. Insights (care gap + operational analytics)
      • 6.1.2.3. Models (VBC optimization engines)
    • 6.1.3. Retail Pharmacies
      • 6.1.3.1. Data (patient + prescription + adherence signals)
      • 6.1.3.2. Insights (patient behavior / refill optimization)
      • 6.1.3.3. Models (adherence / engagement engines)
    • 6.1.4. Other Non-Payer Healthcare Entities
      • 6.1.4.1. Data packages
      • 6.1.4.2. Insights platforms
      • 6.1.4.3. API / embedded models
  • 6.2. By Contract Structure
    • 6.2.1. Annual license
    • 6.2.2. Per-query / API-based
    • 6.2.3. Subscription vs bulk licensing
  • 6.3. Cross-Cutting Pricing Questions & Premium Drivers

Chapter 7. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer Demand & WTP Ranking

  • 7.1. Ranking by Buyer & Product Type Segment
    • 7.1.1. Willingness to Pay (WTP) Analysis Anchors
  • 7.2. Observable Demand Signals
    • 7.2.1. Published or disclosed contract values
    • 7.2.2. Request for proposal (RFP) trends
    • 7.2.3. Transaction comps for comparable payer-adjacent data assets
  • 7.3. Adoption Benchmarks
    • 7.3.1. Average sales cycle length by buyer segment
    • 7.3.2. Time-to-first-deal for comparable new entrants
    • 7.3.3. Product-type adoption rates

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Profiles/Listing
    • 8.2.1. Arcadia Solutions, LLC
      • 8.2.1.1. Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Product Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Inovalon
      • 8.2.2.1. Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Product Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. IQVIA
      • 8.2.3.1. Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Product Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Optum, Inc.
      • 8.2.4.1. Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Product Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Komodo Health, Inc.
      • 8.2.5.1. Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Product Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Cotiviti, Inc.
      • 8.2.6.1. Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Product Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. Symphony Health
      • 8.2.7.1. Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Product Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Definitive Healthcare
      • 8.2.8.1. Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Product Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. Truveta
      • 8.2.9.1. Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Product Benchmarking
      • 8.2.9.4. Strategic Initiatives
  • 8.3. Monetization Models Overview
      • 8.3.1.1. Assessment across data, insights, and model-driven offerings
      • 8.3.1.2. Directional view of pricing approaches and commercialization model
      • 8.3.1.3. Pricing Mechanism Taxonomy
      • 8.3.1.4. Company-Level Commercialization Model Summary
      • 8.3.1.5. Directional ACV Benchmarking Summary
      • 8.3.1.6. Key Commercial Dynamics & Implications

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence, by entity, 2021 - 2033 (USD Million)
  • Table 4 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence, by product type, 2021 - 2033 (USD Million)
  • Table 5 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence, by buyer type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot, 2025 (USD Million)
  • Fig. 9 Market segmentation insights
  • Fig. 10 Competitive landscape
  • Fig. 11 Market driver impact
  • Fig. 12 Market restraint impact
  • Fig. 13 Porter's analysis
  • Fig. 14 PESTLE analysis
  • Fig. 15 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Total Addressable Market (TAM) outlook and key takeaways
  • Fig. 16 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
  • Fig. 17 Healthcare entities market, 2021 - 2033 (USD Million)
  • Fig. 18 Non-healthcare entities market, 2021 - 2033 (USD Million)
  • Fig. 19 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Serviceable Available Market (SAM) outlook and key takeaways
  • Fig. 20 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
  • Fig. 21 Healthcare entities market, 2021 - 2033 (USD Million)
  • Fig. 22 Non-healthcare entities market, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Serviceable Obtainable Market (SOM) outlook and key takeaways
  • Fig. 24 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
  • Fig. 25 Healthcare entities market, 2021 - 2033 (USD Million)
  • Fig. 26 Non-healthcare entities market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
  • Fig. 28 U.S. Healthcare Entities Market, by Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 29 U.S. Healthcare Entities Market, by Buyer Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Healthcare Entities Market, by Pharmaceutical Companies, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 31 U.S. Healthcare Entities Market, by Health Systems & Providers, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Healthcare Entities Market, by Retail Pharmacies, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 33 U.S. Healthcare Entities Market, by Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Healthcare Entities Market, by Buyer, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Healthcare Entities Market, by Pharmaceutical Companies, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 36 U.S. Healthcare Entities Market, by Health Systems & Providers, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Healthcare Entities Market, by Retail Pharmacies, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 38 U.S. Pharmaceutical Companies, by Clinical Trial Enablement, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Pharmaceutical Companies, by HCP & Customer Targeting, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 40 U.S. Pharmaceutical Companies, by Safety, Adherence & HEOR, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Pharmaceutical Companies, by Formulary Analytics/Commercial Access Enablement, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 42 U.S. Health Systems & Providers, Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 43 U.S. Retail Pharmacies, Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 44 U.S. Other Non-Payer Healthcare Entities, Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
  • Fig. 45 U.S. Pharmaceutical Companies, by Clinical Trial Enablement, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 46 U.S. Pharmaceutical Companies, by HCP & Customer Targeting, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Pharmaceutical Companies, by Safety, Adherence & HEOR, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 48 U.S. Pharmaceutical Companies, by Formulary Analytics/Commercial Access Enablement, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 49 U.S. Health Systems & Providers, Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 50 U.S. Retail Pharmacies, Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
  • Fig. 51 U.S. Other Non-Payer Healthcare Entities, Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)